

Press release

Zug, 22 July 2008

Significant cooperation agreement for portfolio company PTC Therapeutics

PTC Therapeutics, one of HBM BioVentures' larger private portfolio positions, has announced a major cooperation agreement with biotechnology company Genzyme. The alliance concerns the PTC124 product candidate that is currently in Phase IIb clinical development for the treatment of genetic conditions. PTC124 is one of several promising product candidates from PTC Therapeutics. Under the terms of the agreement, the company will receive an immediate payment of USD 100 million. Subject to successful continued product development, the company stands to gain a further USD 337 million in milestone-related payments, as well as a double digit royalty income.

The cooperation agreement gives PTC Therapeutics an experienced partner for the continued development and marketing of PTC124. Under the agreement, PTC will retain marketing rights in the major US and Canadian markets, while Genzyme is granted such rights for all other markets. The payments to PTC should finance product development through to approval.

HBM BioVentures has built up its investment in PTC Therapeutics over several rounds of financing. After the Genzyme deal PTC will have some USD 130 million in cash whereas the company is valued at around USD 140 million. Despite this transaction, the strict application of EVCA and IFRS valuation standards do not allow to revalue this position.

To find out more, please visit the PTC Therapeutics Inc. website at www.ptcbio.com.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

Brief profile of HBM BioVentures Ltd

As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on private equity, with two-thirds of its CHF 1 billion capital invested in

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SWX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SWX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation. A public share offer in the USA would be conducted by means of a prospectus that would be available from HBM BioVentures Ltd and would contain detailed information about the Company and its management, as well as the annual financial statements.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com